Biotech Values

[frontiers]

(what if) ACHN's production lots contain 1%, 0.1%, or 0.01% of non-deuterated material

The ACHN patent application covers levels of deuterium enrichment at the claimed positions (5-prime of ribose and uridine) of 50-99% in various embodiments. Hence the point you brought up is not a concern if the patent is allowed ... which I expect it will be, based on the four separate benefits of deuteration that are shown in the examples.